Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: -1.50 (-2.31%)
Spread: 3.00 (4.839%)
Open: 65.00
High: 65.00
Low: 63.50
Prev. Close: 65.00
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Recommended Offer for Anker

24 Aug 2005 12:11

Torex Retail PLC24 August 2005 Torex Retail Plc24 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR ANKER PLC Offer Wholly Unconditional and Compulsory Acquisition of Outstanding Anker Shares The Board of Torex Retail Plc ("Torex Retail") announces that the offer (the"Offer") made by UBS Investment Bank on behalf of Torex Retail for Anker Plc("Anker") has today become wholly unconditional. As at 3.00 p.m. on 23 August 2005, Anker had received valid acceptances of theoffer in respect of a total of 41,177,970 Anker Shares, representingapproximately 99.02 per cent. of the existing issued share capital of Anker. As at 3.00 p.m. on 23 August 2005, valid acceptance of the Offer in relation to8,292,325 Anker Shares, representing 19.94 per cent. of the existing issuedordinary share capital of Anker, had been received electing for the basic termsof the Offer, valid acceptances of the Offer in relation 26,192,409 AnkerShares, representing approximately 62.99 per cent. of the existing issuedordinary share capital of Anker, had been received electing for additional cashunder the Mix and Match Facility and valid acceptances of the Offer in relation6,693,236 Anker Shares, representing approximately 16.10 per cent. of theexisting issued ordinary share capital of Anker, had been received electing foradditional New Torex Retail Shares under the Mix and Match Facility. Prior to the posting of the Offer Document on 22 July 2005, Torex Retail hadreceived irrevocable undertakings or letters of intent from the Anker Directorsand certain other Anker Shareholders to accept or procure the acceptance of theOffer in respect of, in aggregate, 31,347,988 Anker Shares, representingapproximately 75.4 per cent. of the existing issued ordinary share capital ofAnker. Included in the valid acceptances of the Offer set out above areacceptances in respect of 31,347,988 Anker Shares, representing approximately75.4 per cent. of the existing issued ordinary share capital of Anker, receivedpursuant to such irrevocable undertakings and letters of intent. Neither Torex Retail nor any persons deemed to be acting in concert with it forthe purposes of the Offer owned any Anker Shares (or rights over such shares) on29 June 2005 (being the last dealing day prior to the commencement of the Offerperiod) nor has Torex Retail nor any person deemed to be acting in concert withit for the purposes of the Offer acquired or agreed to acquire any Anker Shares(or rights over such shares) during the Offer period other than by way ofacceptances of the Offer. Compulsory Acquisition and cancellation of listing As described in the Offer Document, as and when Torex Retail receivesacceptances under the Offer in respect of, and/or otherwise acquired 90 percent. or more of the Anker Shares to which the Offer related, Torex Retailintends to exercise its rights pursuant to the provisions of sections 428 to430F of the Companies Act 1985 to acquire compulsorily Anker Shares in respectof which acceptances have not been received. Accordingly, Torex Retail is today issuing notices under s.429 of the CompaniesAct 1985 to Anker Shareholders who have not yet accepted the Offer that it nowintends to exercise its rights to acquire compulsorily all of those Anker Sharesstill outstanding at the expiry of the requisite notice period. In themeantime, the Offer remains open for acceptance until further notice, althoughthe Mix and Match Facility is now closed. Notice has also been sent to the Board of Anker requesting that the AnkerDirectors make an application to AIM for cancellation of the admission totrading of Anker Shares on AIM. It is expected that such cancellation willbecome effective after 20 clear business days following this announcement on the20 September 2005. For Anker Shares held in certificated form, Forms of Acceptance should becompleted, signed and returned in accordance with instructions set out in theOffer Document and in the Form of Acceptance, so as to be received as soon aspossible. For Anker Shares held in uncertificated form, an Electronic Acceptanceshould be made in accordance with instructions set out in the Offer Document sothat the TTE Instruction settles as soon as possible. Settlement of consideration Settlement of consideration to which any Anker Shareholder is entitled will beeffected: (i) in the case of acceptances received (complete in all respects) by23 August 2005 within 7 days of this date; or (ii) in the case of acceptancesreceived (complete in all respects) after 23 August 2005 but while the Offerremains open, within 7 days of such receipt. Terms defined in the offer document dated 22 July 2005 (the "Offer Document")shall, unless the context requires otherwise, have the same meanings in thisannouncement. EnquiriesTorex Retail Plc Telephone: 01295 753313Richard Thompson / Nigel Horn UBS Investment Bank Telephone: 0207 567 8000Ben Robertson / Jackie Lee This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Oct 20143:35 pmRNSInitial Clinical Trial Results
10th Sep 20149:00 amRNSdCELL® technology presented at Royal Society event
30th Jul 20147:00 amRNSUK meniscus clinical trial & DermaPure US updates
25th Jul 20147:00 amRNSTissue Regenix adds European bladder matrix patent
18th Jul 201411:11 amRNSIssue of equity and total voting rights
27th Jun 20143:06 pmRNSResult of AGM
12th Jun 20147:00 amRNSTissue Regenix announces launch of DermaPure in US
22nd May 20147:00 amRNSPreliminary Decision to Approve "Q" Code Request
20th May 20147:00 amRNSDeferred Annual Bonus Award
19th May 201410:21 amRNSAnnual Report & Accounts and Notice of AGM
19th May 20147:00 amRNSPreliminary results for year ended 31 January 2014
16th May 20141:00 pmRNSTissue Regenix adds US patent
12th May 201411:00 amRNSNotice of Preliminary Results
30th Apr 20145:14 pmRNSHolding(s) in Company
28th Apr 20147:00 amRNSTissue Regenix adds Chinese patent
24th Apr 20148:40 amRNSHolding(s) in Company
4th Feb 20143:03 pmRNSIssue of Share Options
31st Jan 20141:11 pmRNSHolding(s) in Company
14th Jan 20145:22 pmRNSIssue of equity and total voting rights
9th Jan 201411:11 amRNSIssue of equity and total voting rights
19th Dec 20137:00 amRNSTissue Regenix to attend JPMorgan Healthcare Event
12th Dec 20137:00 amRNSTissue Regenix signs US distribution agreements
22nd Nov 20137:00 amRNSDirector Share Purchase
29th Oct 20137:00 amRNSPresentation at Proactiveinvestors Forum in Dublin
28th Oct 20134:49 pmRNSDirector Share Purchase
21st Oct 20137:00 amRNSPublication of DermaPure UK trial results
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
14th Oct 20137:00 amRNSTissue Regenix USA successful technology transfer
8th Oct 20137:00 amRNSInterim Results for six months ended 31 July 2013
12th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Marketing
6th Aug 20139:41 amRNSHolding(s) in Company
5th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Operations
29th Jul 20138:45 amRNSTissue Regenix Key Appointment at USA Subsidiary
25th Jul 20134:59 pmRNSHolding(s) in Company
17th Jul 20137:00 amRNSAppointment of Non-Executive Director
10th Jul 20137:00 amRNSAppointment of Non-Executive Director
18th Jun 20137:00 amRNSTissue Regenix advances US commercialisation
14th Jun 201312:43 pmRNSResult of AGM
14th Jun 20137:00 amRNSPresentation of dCELL at heart valve event
28th May 20137:00 amRNSAppointment of Business Development Manager
14th May 20133:47 pmRNSAnnual Report and Notice of AGM
13th May 20137:00 amRNSPreliminary results for the year ended 31 Jan 2013
3rd May 20137:00 amRNSNotice of Results
2nd May 20137:00 amRNSResults of dCELL Dermis trial
29th Apr 20137:00 amRNSChange of Nominated Adviser and Broker
16th Apr 20137:00 amRNSApproval for start of clinical research trial
2nd Apr 20137:00 amRNSTissue Regenix makes appointment to US subsidiary
11th Mar 20137:00 amRNSDirector Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.